Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

CureVac begins CV9104 Phase 2b clinical trial in patients with castration-resistant prostate cancer

CureVac GmbH, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA, today announced that it has initiated a double-blind, randomized Phase 2b clinical trial of its RNActive cancer vaccine, CV9104, for the treatment of patients with castration-resistant prostate cancer.

28 Mar 2013

Researchers identify patterns of mutations in early stage node negative lung adenocarcinoma

Molecular driven therapeutic targets have resulted in a paradigm shift in the treatment of advanced lung adenocarcinoma. However, in early non-small cell lung cancer, surgical resection remains the treatment of choice with adjuvant chemotherapy.

25 Mar 2013

Results from GTx's Phase 2 clinical trial of enobosarm published online

GTx, Inc. today announced that the journal, The Lancet Oncology, has published online ahead of its April print edition the results from GTx's randomized, double-blind, placebo-controlled Phase 2 clinical trial of enobosarm to assess its effects on muscle wasting and physical function in patients with cancer.

15 Mar 2013

Global Blood Therapeutics, Array BioPharma partner for drug discovery research

Array BioPharma Inc. and Global Blood Therapeutics today announced a multi-target drug discovery collaboration agreement to identify small molecule lead compounds targeting chronic blood-based diseases.

6 Mar 2013

Better representation of elderly patients in phase III trials can improve evidence-based treatment

The median age of patients diagnosed with advanced non-small-cell lung cancer (NSCLC) has steadily increased over the recent years and is presently 70 years. Despite this, the elderly are significantly underrepresented in clinical trials.

25 Feb 2013

Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon Biopharmaceuticals

ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.

20 Feb 2013

IKBKE gene plays a key role in tobacco-induced lung cancer

Researchers at Moffitt Cancer Center have found a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. It is based on the newly identified oncogene IKBKE, which helps regulate immune response.

16 Feb 2013

SUVmax may help indicate progression-free survival in stage I NSCLC patients treated with SBRT

SUVmax (Maximum Standardized Uptake Value) may be a significant and clinically independent marker to indicate progression-free survival in stage I non-small cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT), according to research being presented at the 2013 Cancer Imaging and Radiation Therapy Symposium.

10 Feb 2013

Positive data from Oncolytics' REOLYSIN Phase 2 combination trial on SCCLC

Oncolytics Biotech Inc. today announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021).

9 Feb 2013

Start palliative care early for optimum results

Palliative care provided early in the ambulatory care setting varies with the trajectory of patients’ disease and is complementary to medical management, show study results.

6 Feb 2013

RRM1 gene may better predict survival for pancreatic adenocarcinoma

Moffitt Cancer Center researchers have identified a gene that may better predict survival for pancreatic adenocarcinoma, the fourth leading cause of cancer deaths in the United States.

6 Feb 2013

Cerulean initiates CRLX101 Phase 2 study in extensive-stage small cell lung cancer

Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

31 Jan 2013

Phenformin decreases size of lung tumors and increases survival in mice

Ever since discovering a decade ago that a gene altered in lung cancer regulated an enzyme used in therapies against diabetes, Reuben Shaw has wondered if drugs originally designed to treat metabolic diseases could also work against cancer.

30 Jan 2013

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

22 Jan 2013

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim today announced that the New Drug Application (NDA) for its investigational oncology compound afatinib has been accepted for filing and granted Priority Review by the U.S. Food and Drug Administration (FDA).

17 Jan 2013

Astellas announces FDA acceptance of Tarceva sNDA for EGFR activating mutation-positive NSCLC

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental New Drug Application (sNDA) for Tarceva (erlotinib) for first-line use in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) activating mutations.

17 Jan 2013

Study: Patients with EGFR exon 20 insertions need targeted therapies

Exon 20 insertions are the third most common family of epidermal growth factor receptor (EGFR) mutations found in non-small-cell lung cancer (NSCLC). Little is known about cancers harboring these mutations aside from their lack of response to EGFR tyrosine kinase inhibitors, impairing the development of effective targeted therapies. A recent study published in the February 2013 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, concludes that patients with EGFR exon 20 insertions have similar clinical characteristics to those with common EGFR mutations, but a poorer prognosis.

16 Jan 2013

Beta blocker use linked to NSCLC patient survival

Beta blockers may boost survival in patients undergoing definitive radiotherapy for non-small-cell lung cancer, suggests research published in the Annals of Oncology.

14 Jan 2013

Seven scientists named 2013 recipients of Damon Runyon-Rachleff Innovation Award

The Damon Runyon Cancer Research Foundation announced that seven scientists with novel approaches to fighting cancer have been named 2013 recipients of the Damon Runyon-Rachleff Innovation Award.

8 Jan 2013

Industry sponsored drug and device studies: an interview with Professor Lisa Bero

Our review included analyses of drug and device studies conducted in humans. The drugs or devices could be compared to placebo or sham treatments, or other effective treatments. The drugs and devices examined for this review are used for a wide variety of clinical conditions, including cardiovascular and psychiatric diseases.

7 Jan 2013